Compare TFII & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFII | BIO |
|---|---|---|
| Founded | 1957 | 1952 |
| Country | Canada | United States |
| Employees | N/A | 7450 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.1B |
| IPO Year | 2012 | N/A |
| Metric | TFII | BIO |
|---|---|---|
| Price | $133.78 | $256.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $146.50 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 348.4K | 284.7K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.16 | $2.74 |
| Revenue Next Year | $4.68 | $3.20 |
| P/E Ratio | $31.26 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.27 | $211.43 |
| 52 Week High | $149.09 | $343.12 |
| Indicator | TFII | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.79 | 34.62 |
| Support Level | $84.30 | $246.01 |
| Resistance Level | N/A | $289.61 |
| Average True Range (ATR) | 4.20 | 10.58 |
| MACD | -0.02 | -4.56 |
| Stochastic Oscillator | 42.96 | 18.56 |
TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customer's specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.